Welcome
IP Law News

Gilead Denies CDC Earned Cut of Billions Made Off Truvada Patent

Jan. 24, 2020, 5:36 PM

Gilead shouldn’t have to share the billions it reaped from its HIV prevention drugs with the federal government, the company told a federal judge.

The company denied that researchers with the Centers for Disease Control and Prevention “succeeded where others had not” in their development of the Pre-Exposure Prophylaxis (PrEP) treatment for preventing HIV, according to a response filed Thursday in the U.S. District Court for the District of Delaware. Gilead alleges the federal government isn’t entitled to a “reasonable royalty” for its work on the medication that became Truvada or that the CDC alone provided any “breakthrough work.”

Gilead’s...

To read the full article log in. To learn more about a subscription click here.